Lung
Tropion-Lung15
A Phase III, Open Label, Sponsor-Blind, Randomized Study of Dato DXd With or Without osimertinib Versus Platinum-Based Doublet Chemotherapy for Patients with EGFR-mutated Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed on Prior osimertinib Treatment .
Trial overview
Clinical Area
Medical Oncology
Disease
Non-small cell lung cancer (NSCLC)
Disease site
Lung & bronchus
Study Phase
III
Trial Identifiers
Registration number: NCT06417814
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries